(Q42984305)

English

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.

scientific article published on January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Masanori Atsukawa

1

1 reference

Europe PubMed Central

12 November 2017

Akihito Tsubota

2

1 reference

Europe PubMed Central

12 November 2017

Chisa Kondo

3

1 reference

Europe PubMed Central

12 November 2017

Norio Itokawa

4

1 reference

Europe PubMed Central

12 November 2017

Yoshiyuki Narahara

5

1 reference

Europe PubMed Central

12 November 2017

Katsuhisa Nakatsuka

6

1 reference

Europe PubMed Central

12 November 2017

Satomi Hashimoto

7

1 reference

Europe PubMed Central

12 November 2017

Takeshi Fukuda

8

1 reference

Europe PubMed Central

12 November 2017

Yoko Matsushita

9

1 reference

Europe PubMed Central

12 November 2017

Hideko Kidokoro

10

1 reference

Europe PubMed Central

12 November 2017

Tamaki Kobayashi

11

1 reference

Europe PubMed Central

12 November 2017

Hidenori Kanazawa

12

1 reference

Europe PubMed Central

12 November 2017

Choitsu Sakamoto

13

1 reference

Europe PubMed Central

12 November 2017

publication date

1 January 2013

1 reference

Europe PubMed Central

12 November 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

12 November 2017

28

1 reference

Europe PubMed Central

12 November 2017

1

1 reference

Europe PubMed Central

12 November 2017

51-56

1 reference

Europe PubMed Central

12 November 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Identifying HCV genotype 1 patients at risk of relapse

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Fluvastatin inhibits hepatitis C replication in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2012.07267.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2012.07267.X

1 reference

Europe PubMed Central

12 November 2017

release_o2d2nyd745gs7e2oskc2fapg3e

1 reference

https://api.fatcat.wiki/v0/release/o2d2nyd745gs7e2oskc2fapg3e

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42984305&oldid=1842427589"